Achillion Pharmaceuticals, a developer of small molecule drugs, has received a Phase I Small Business Innovation Research, or SBIR, Grant from the National Institute of Allergy and Infectious Disease branch of the National Institutes of Health, or NIH, ...
[Published Mar 19 2010 by TradingMarkets]